United Therapeutics Stock Probability Of Bankruptcy

UTHR Stock

USD 378.13 1.13 0.30%

United Therapeutics' chance of distress is below 1% at this time. The company is very unlikely to encounter any financial hardship in the next two years. United Therapeutics' Probability of distress is determined by interpolating and adjusting United Altman Z Score to account for off-balance-sheet items and missing or unfiled public information. All items used in analyzing the odds of distress are taken from the United balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out United Therapeutics Piotroski F Score and United Therapeutics Altman Z Score analysis.

To learn how to invest in United Stock, please use our How to Invest in United Therapeutics guide.

As of 11/29/2024, Market Cap is likely to grow to about 12 B. Also, Enterprise Value is likely to grow to about 11.8 B

United Therapeutics Company probability of distress Analysis

United Therapeutics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Probability Of Bankruptcy

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current United Therapeutics Probability Of Bankruptcy

Less than 1%

Most of United Therapeutics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, United Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Our calculation of United Therapeutics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting United Therapeutics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of United Therapeutics financial health.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of United Therapeutics. If investors know United will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about United Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.188

Earnings Share

22.76

Revenue Per Share

60.245

Quarterly Revenue Growth

0.229

Return On Assets

0.1189

The market value of United Therapeutics is measured differently than its book value, which is the value of United that is recorded on the company's balance sheet. Investors also form their own opinion of United Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is United Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because United Therapeutics' market value can be influenced by many factors that don't directly affect United Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between United Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if United Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, United Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

United Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for United Therapeutics is extremely important. It helps to project a fair market value of United Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since United Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of United Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of United Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Good Will	Short Term Investments	Short Term Debt	Intangible Assets	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.14	0.97	-0.22	0.74	0.89	0.99	0.92	0.95	0.83	0.48	0.47	0.57	-0.69	0.96	0.4	0.98	0.82	0.82	0.93	0.91	0.91	0.89	-0.86
Total Stockholder Equity	1.0		-0.19	0.98	-0.22	0.74	0.85	0.99	0.91	0.95	0.81	0.47	0.43	0.52	-0.68	0.95	0.37	0.99	0.8	0.81	0.92	0.91	0.91	0.89	-0.84
Net Debt	-0.14	-0.19		-0.26	0.12	-0.58	0.12	-0.23	-0.01	0.06	0.13	0.03	-0.28	0.45	0.41	-0.17	0.05	-0.15	0.03	-0.34	0.11	-0.03	0.01	0.01	-0.2
Retained Earnings	0.97	0.98	-0.26		-0.28	0.78	0.83	0.98	0.92	0.89	0.75	0.54	0.46	0.55	-0.8	0.94	0.22	0.97	0.81	0.87	0.87	0.91	0.88	0.86	-0.83
Accounts Payable	-0.22	-0.22	0.12	-0.28		-0.21	-0.2	-0.26	-0.13	-0.2	0.02	0.05	0.06	-0.11	0.28	-0.15	0.14	-0.27	-0.23	-0.36	-0.22	-0.25	-0.28	-0.26	0.32
Net Receivables	0.74	0.74	-0.58	0.78	-0.21		0.63	0.77	0.59	0.54	0.56	0.26	0.65	0.18	-0.76	0.78	0.3	0.69	0.48	0.74	0.55	0.61	0.51	0.5	-0.41
Total Liab	0.89	0.85	0.12	0.83	-0.2	0.63		0.85	0.84	0.83	0.82	0.46	0.6	0.74	-0.68	0.91	0.49	0.82	0.83	0.75	0.84	0.79	0.8	0.77	-0.88
Total Current Assets	0.99	0.99	-0.23	0.98	-0.26	0.77	0.85		0.89	0.94	0.78	0.45	0.47	0.53	-0.73	0.95	0.36	0.98	0.8	0.84	0.88	0.89	0.9	0.9	-0.83
Good Will	0.92	0.91	-0.01	0.92	-0.13	0.59	0.84	0.89		0.88	0.76	0.73	0.47	0.64	-0.74	0.93	0.22	0.89	0.78	0.79	0.84	0.85	0.83	0.8	-0.83
Short Term Investments	0.95	0.95	0.06	0.89	-0.2	0.54	0.83	0.94	0.88		0.81	0.42	0.31	0.6	-0.52	0.88	0.4	0.96	0.78	0.7	0.93	0.87	0.94	0.95	-0.86
Short Term Debt	0.83	0.81	0.13	0.75	0.02	0.56	0.82	0.78	0.76	0.81		0.35	0.47	0.61	-0.46	0.81	0.46	0.79	0.65	0.53	0.85	0.86	0.75	0.73	-0.72
Intangible Assets	0.48	0.47	0.03	0.54	0.05	0.26	0.46	0.45	0.73	0.42	0.35		0.32	0.38	-0.59	0.55	-0.13	0.43	0.45	0.51	0.36	0.48	0.37	0.31	-0.48
Common Stock	0.47	0.43	-0.28	0.46	0.06	0.65	0.6	0.47	0.47	0.31	0.47	0.32		0.35	-0.65	0.64	0.47	0.35	0.48	0.65	0.26	0.3	0.36	0.33	-0.29
Long Term Debt	0.57	0.52	0.45	0.55	-0.11	0.18	0.74	0.53	0.64	0.6	0.61	0.38	0.35		-0.54	0.55	0.14	0.54	0.78	0.55	0.62	0.64	0.63	0.65	-0.78
Treasury Stock	-0.69	-0.68	0.41	-0.8	0.28	-0.76	-0.68	-0.73	-0.74	-0.52	-0.46	-0.59	-0.65	-0.54		-0.75	0.04	-0.65	-0.69	-0.89	-0.48	-0.66	-0.55	-0.54	0.59
Property Plant Equipment	0.96	0.95	-0.17	0.94	-0.15	0.78	0.91	0.95	0.93	0.88	0.81	0.55	0.64	0.55	-0.75		0.46	0.91	0.76	0.82	0.84	0.82	0.82	0.79	-0.79
Current Deferred Revenue	0.4	0.37	0.05	0.22	0.14	0.3	0.49	0.36	0.22	0.4	0.46	-0.13	0.47	0.14	0.04	0.46		0.31	0.24	0.16	0.4	0.15	0.31	0.3	-0.25
Net Tangible Assets	0.98	0.99	-0.15	0.97	-0.27	0.69	0.82	0.98	0.89	0.96	0.79	0.43	0.35	0.54	-0.65	0.91	0.31		0.8	0.79	0.94	0.92	0.93	0.92	-0.85
Long Term Debt Total	0.82	0.8	0.03	0.81	-0.23	0.48	0.83	0.8	0.78	0.78	0.65	0.45	0.48	0.78	-0.69	0.76	0.24	0.8		0.87	0.78	0.81	0.9	0.85	-0.91
Capital Surpluse	0.82	0.81	-0.34	0.87	-0.36	0.74	0.75	0.84	0.79	0.7	0.53	0.51	0.65	0.55	-0.89	0.82	0.16	0.79	0.87		0.65	0.74	0.8	0.76	-0.72
Long Term Investments	0.93	0.92	0.11	0.87	-0.22	0.55	0.84	0.88	0.84	0.93	0.85	0.36	0.26	0.62	-0.48	0.84	0.4	0.94	0.78	0.65		0.9	0.91	0.86	-0.88
Short Long Term Debt	0.91	0.91	-0.03	0.91	-0.25	0.61	0.79	0.89	0.85	0.87	0.86	0.48	0.3	0.64	-0.66	0.82	0.15	0.92	0.81	0.74	0.9		0.87	0.84	-0.85
Net Invested Capital	0.91	0.91	0.01	0.88	-0.28	0.51	0.8	0.9	0.83	0.94	0.75	0.37	0.36	0.63	-0.55	0.82	0.31	0.93	0.9	0.8	0.91	0.87		0.97	-0.89
Net Working Capital	0.89	0.89	0.01	0.86	-0.26	0.5	0.77	0.9	0.8	0.95	0.73	0.31	0.33	0.65	-0.54	0.79	0.3	0.92	0.85	0.76	0.86	0.84	0.97		-0.84
Capital Stock	-0.86	-0.84	-0.2	-0.83	0.32	-0.41	-0.88	-0.83	-0.83	-0.86	-0.72	-0.48	-0.29	-0.78	0.59	-0.79	-0.25	-0.85	-0.91	-0.72	-0.88	-0.85	-0.89	-0.84

Click cells to compare fundamentals

The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.

Competition

Predict United Therapeutics

Based on the latest financial disclosure, United Therapeutics has a Probability Of Bankruptcy of 1.0%. This is 97.69% lower than that of the Biotechnology sector and 98.18% lower than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 97.49% higher than that of the company.

United Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses United Therapeutics' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of United Therapeutics could also be used in its relative valuation, which is a method of valuing United Therapeutics by comparing valuation metrics of similar companies.

United Therapeutics is currently under evaluation in probability of bankruptcy category among its peers.

United Therapeutics Main Bankruptcy Drivers

	2019	2020	2021	2022	2023	2024 (projected)
Return On Assets	0.15	0.17	(0.0267)	0.11	0.092	0.12
Asset Turnover	0.6	0.48	0.37	0.32	0.33	0.29
Net Debt	111.6M	61.3M	(94.8M)	(161.2M)	(507.7M)	(482.3M)
Total Current Liabilities	463M	323.3M	305.4M	343.2M	804.4M	844.6M
Non Current Liabilities Total	670M	896.5M	904.8M	904.6M	377.8M	269.4M
Total Assets	3.9B	4.6B	5.2B	6.0B	7.2B	7.5B
Total Current Assets	1.9B	2.2B	2.3B	3.4B	3.6B	3.7B
Total Cash From Operating Activities	(206.6M)	755.7M	598.2M	802.5M	978M	1.0B

United Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, United Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to United Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

United Fundamentals

	Return On Equity	0.19
	Return On Asset	0.12
	Profit Margin	0.40 %
	Operating Margin	0.55 %
	Current Valuation	13.95 B
	Shares Outstanding	44.64 M
	Shares Owned By Insiders	1.84 %
	Shares Owned By Institutions	98.16 %
	Number Of Shares Shorted	2.21 M
	Price To Earning	23.49 X
	Price To Book	2.77 X
	Price To Sales	6.12 X
	Revenue	2.33 B
	Gross Profit	1.78 B
	EBITDA	1.39 B
	Net Income	984.8 M
	Cash And Equivalents	2.26 B
	Cash Per Share	49.55 X
	Total Debt	700 M
	Debt To Equity	0.18 %
	Current Ratio	8.10 X
	Book Value Per Share	136.74 X
	Cash Flow From Operations	978 M
	Short Ratio	5.72 X
	Earnings Per Share	22.76 X
	Price To Earnings To Growth	1.63 X
	Target Price	382.22
	Number Of Employees	1.17 K
	Beta	0.56
	Market Capitalization	16.88 B
	Total Asset	7.17 B
	Retained Earnings	6.03 B
	Working Capital	2.75 B
	Current Asset	1.28 B
	Current Liabilities	440.82 M
	Net Asset	7.17 B

About United Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze United Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of United Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of United Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with United Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if United Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in United Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with United Stock

0.64	EWTX	Edgewise Therapeutics	Pair Corr
0.65	BHC	Bausch Health Companies	Pair Corr

Moving against United Stock

0.7	HLN	Haleon plc	Pair Corr
0.67	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.65	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.65	ZTS	Zoetis Inc	Pair Corr
0.57	LLY	Eli Lilly Sell-off Trend	Pair Corr

The ability to find closely correlated positions to United Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace United Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back United Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling United Therapeutics to buy it.

The correlation of United Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as United Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if United Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for United Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

United Therapeutics Stock Probability Of Bankruptcy

United Therapeutics Company probability of distress Analysis

Probability Of Bankruptcy

Normalized

Z-Score

Current United Therapeutics Probability Of Bankruptcy

United Probability Of Bankruptcy Driver Correlations

United Probability Of Bankruptcy Peer Comparison

United Therapeutics Main Bankruptcy Drivers

United Therapeutics ESG Sustainability

United Fundamentals

About United Therapeutics Fundamental Analysis

Pair Trading with United Therapeutics

Moving together with United Stock

Moving against United Stock

Additional Tools for United Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY